R-Tech Ueno has completed the subject enrollment for the phase 2 clinical study of 0.15% UF-021 (generic name; isopropyl unoprostone; active ingredient of Rescula eye-drops), in patients with retinitis pigmentosa.
The company said that the enrollment in the phase 2 study has begun at six clinical sites in late December 2008, and was completed on August 3, 2009.
Reportedly, the company developed and launched isopropyl unoprostone eye-drops on the market as a drug for glaucoma and ocular hypertension in 1994.
Moreover, the company expects isopropyl unoprostone to become a unique drug for improvement of the quality of vision in patients with retinitis pigmentosa.